Establishment of murine cell line transfected with human CD14 gene.
- Author:
Bo-Tao NING
1
;
Yong-Min TANG
;
Yan XU
;
Yan-Fei CHEN
;
Jiang CAO
Author Information
1. Department of Hematology and Oncology, Children's Hospital Affiliated to Zhejiang University, Hangzhon 310003, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, Neoplasm;
biosynthesis;
genetics;
Eukaryotic Cells;
metabolism;
Gene Transfer Techniques;
Genetic Vectors;
genetics;
Humans;
Leukemia, Monocytic, Acute;
genetics;
Lipopolysaccharide Receptors;
genetics;
Melanoma, Experimental;
genetics;
metabolism;
pathology;
Mice;
Mice, Inbred C57BL;
Transfection;
Tumor Cells, Cultured
- From:
Journal of Experimental Hematology
2006;14(2):388-391
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to construct the CD14 eukaryotic expression vector, establish the transgeneic CD14 positive cell line in order to facilitate the establishment of a mouse model of antibody targeting therapy for human acute monocytic leukemia (AML-M(5)). Total RNA extracted from peripheral blood mononuclear cells was treated with RNAase-free DNAase, the human CD14 gene was cloned and sequenced through the RT-PCR and T-A clone techniques. Eukaryotic expressional vector pcDNA3.1(+)/CD14 was constructed by cleaving with double restriction endonuleases and ligating with T4 ligase. A murine melanoma cell line B16 was transfected with the pcDNA3.1(+)/CD14 recombinant with Superfect transfection reagent. Positive clones were selected by G418 and the expression of human CD14 on the transfectant was confirmed by flow cytometry (FCM). The results indicated that the sequence of the human CD14 cDNA cloned was exact to be same as the one from GenBank database. The recombinant pcDNA3.1(+)/CD14 was identified with double-enzyme cleaving. The expression of the human CD14 on the transfectant (B16/CD14) was confirmed by FCM. In conclusion, the murine cell line B16/CD14 fransfected with human CD14 gene has been established which can be used for the study of human AML-M(5) antibody targeting therapy with mouse model.
